Ainos To Initiate Taiwan Clinical Study Of VELDONA For Sjögren's Syndrome, Aims To Complete All Regulatory Approvals For The Study In Q4 Of 2024
Portfolio Pulse from Benzinga Newsdesk
Ainos is set to begin a clinical study in Taiwan for its product VELDONA, targeting Sjögren's Syndrome. The company aims to complete all necessary regulatory approvals by Q4 2024.
September 23, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ainos is initiating a clinical study in Taiwan for VELDONA, targeting Sjögren's Syndrome, with a goal to complete regulatory approvals by Q4 2024.
The initiation of a clinical study for VELDONA in Taiwan represents a significant step for Ainos in expanding its product pipeline. Successful regulatory approvals could lead to market expansion and increased revenues, positively impacting AIMD's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100